Wednesday, November 14, 2012

First Novel SGLT2 inhibitor Forxiga (Dapagliflozin ) for the treatment of type 2 diabetes approved by EMA

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU). FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.



Enter your email address:


Delivered by FeedBurner